Use of Risperdal Consta Among Elderly Patients in Geriatric Settings
Núñez Domínguez L. A., Medical Center of Diagnosis, Pamplona, Navarra, Spain.
Portilla Fernández A., Psychiatric Unit, Mental Heathl Net, Pamplona, Navarra, Spain.
Montes Reula L., Psychiatric Unit, Mental Heathl Net, Pamplona, Navarra, Spain.
The treatment of Behavioral Disorders in Dementia associated with another psychiatric disorder usually is very complicated for several reasons (for example, the use of multiples pharmacological treatment for several organic disorders). These behavioral disorders in many cases produces some psychological distress into the caregivers, leading to admissions into clinical setting to provide appropiate cares. Risperidone has been described as a good therapeutic alternative to control these behavioral alterations and LAI Risperidone could be considered as another alterative treatment. The main purpose of the study is to evaluate the efficacy and tolerability of Long-acting injection Risperidone in the treatment of these disorders in a geriatric population in a geriatric setting. We select a group of patients suffering several types of psychiztric disorder with behavioral disorders in a clinical setting and they begin a treatment with LAI Risperidone. I make a follow-up study (6 months) and we observe very good compliance of treatment, decrease of behavioral disorder and decrease in the use of concomitant treatment.
Behavioral Disorder, Elderly, Long-Acting Risperidone, Tolerability
Catalán R, Penadés R.(2011) Risperidone long-acting injection: safety and efficacy in elderly patients with schizophrenia. J Cent Nerv Syst Dis. 2011 May 18; 3: 95-105
Chang CL, Tzeng DS, Lung FW (2010) Treatment effectiveness and adherence in patients with schizophrenia treated with risperidone long-acting injection. Psychiatry Res. 2010 Nov 30; 180(1): 16-9
Hudson-Jessop P, Hughes B, Brinkley N. (2007) New for old? Risperidone long-acting injection in older patients. Australas Psychiatry; 15(6): 461-4.
Kane J M., Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. (2003) Risperidona inyectable de larga duración: Eficacia y seguridad del primer antipsicótico atípico de acción prolongada. Am J Psychiatry, 160: 1125-1132.
Kissling W, Glue P, Medori R, Simpson S (2007) Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients. Hum Psychopharm, 22: 505-513.
Lasser RA, Bossie CA, Zhu Y, Gharabawi G, Eerdekens M, Davidson M (2004) Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder. Int J Geriat Psych, 19: 898-905.
Lee NY, Kim SH, Cho SJ, Chung YC, Jung IK, Kim CY, Kim DH, Lee DG, Lee YH, Lim WJ, Na YS, Shin SE, Woo JM, Yoon JS, Yoon BH, Ahn YM, Kim YS (2014) A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea. Int Clin Psychopharmacol. 2014 Sep; 29(5): 279-87
Masand PS, Gupta S. (2003) Long-acting injectable antipsychotics in the elderly: guidelines for effective use.Drugs Aging.; 20(15): 1099-110.
McKean A, Monasterio E (2015) Indications of atypical antipsychotics in the elderly. Expert Rev Clin Pharmacol. 2015 Jan; 8(1): 5-7
Sing D, O´Connor D (2009) Depot risperidone in elderly patients: the experience of an Australian aged psychiatry service. 789-792.
Tadger S, Baruch Y, Barak Y (2008) Symptomatic remission in elderly schizophrenia patients with long-acting risperidone. Int Psychogeriatr, 20(6): 1245-50.
Wu YH, Lai CY, Chang YS (2015). Antipsychotic polypharmacy among elderly patients with schizophrenia and dementia during hospitalization at a Taiwanese psychiatric hospital. Psychogeriatrics. 2015 Mar; 15(1): 7-13.